Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Polyhydroxylated bile acids for treatment of biliary disorders

A technology of hydroxycholanic acid and bile acid, which is applied in blood diseases, sensory diseases, extracellular fluid diseases, etc., and can solve problems such as no phenotype

Active Publication Date: 2012-10-03
山东青佰欣达医药科技有限公司
View PDF2 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, while BSEP knockout mice exhibit very mild cholestasis throughout life, mdr1a - / - / mdr1b - / - Double knockout mice are healthy with no apparent phenotype, although they do have specific defects in the biliary excretion of infused drugs known to be Mdr1 substrates (22)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polyhydroxylated bile acids for treatment of biliary disorders
  • Polyhydroxylated bile acids for treatment of biliary disorders
  • Polyhydroxylated bile acids for treatment of biliary disorders

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0085] Preparation of polyhydroxylated bile acids

[0086] Compounds according to the invention or used according to the invention, including pharmaceutically acceptable salts or derivatives thereof, may be obtained synthetically using conventional procedures as described herein or known in the art. The compounds usable according to the invention can be obtained from natural sources. For example, polyhydroxylated bile acid compounds can be prepared in part or in whole from natural sources, eg, by fractionation of biological extracts (eg, from bsep KO mice). Bile acids can be obtained from bsep KO mice by, for example, using a bile duct cannula to collect approximately 10-20 ml of bile from a 50-100 bsep KO mouse. HPLC can be used to separate about 10-20 μmol (5-10 mg) of tetra-hydroxylated bile acids. In some embodiments, polyhydroxylated bile acid compounds according to the invention can be prepared by total synthesis. Alternatively, such synthetic compounds can be labeled...

Embodiment 1

[0107] Example 1: Animal model of cholestasis

[0108] method

[0109] animal

[0110] bsep KO mice based on FVB / NJ genetic background (16) and mdr1a / 1b KO mice (22) were maintained in the laboratory as previously described from Taconic (Hudson, NY 12534). Mice were maintained at 22°C under a 12-hour light-dark cycle and had free access to food and water. Unless otherwise specified in the results, mice were fed a normal diet (chow). The procedure for this experiment was approved by the Animal Ethics Committee of the University of British Columbia and performed according to the guidelines of the Canadian Council for Animal Care.

[0111] Light and TEM

[0112] For light microscopy, after fasting for 2-4 hours with CO 2 Kill the mice. The liver was immediately removed and transferred to 10% neutral buffered formalin solution, followed by paraffin section and hematoxylin-eosin staining or Masson's trichrome staining (Wax-it Histology Services Inc, Vancouver). For trans...

Embodiment 2

[0144] Example 2: Synthesis of taurine-bound 3α, 6β, 7β, 12α-hydroxy bile acids

[0145] As described in (29-31), taurine was synthesized to bind 3α, 6β, 7β, 12α-hydroxybile acids, essentially the 12α-hydroxylated variant of β-muricholate. Isomers are produced simultaneously in the synthesis and may have similar activities. Thus, at least 5 additional derivatives of the above compounds were also isolated, specifically 3α, 6α, 7α, 12α-, 3α, 6β, 7α, 12α-, 3α, 6α, 7β, 12α-, 3α, 6β, 7β, 12α-, 3α, 6α, 7α, 12β-hydroxy derivatives. The isolated compounds were labeled with 3H-labeled bile salts by hydrogen exchange in a solution enriched in tritium water followed by reisolation of the labeled bile salts (available from Perkin-Elmer) (32). The relative affinities of isolated compounds for in vitro transport via MDR1 were tested as described herein. The most potent compounds were isolated in large quantities in vitro and used as lead compounds for in vivo testing of toxicity and effi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides, in part, polyhydroxylated bile acids for treating biliary disorders, for example, biliary disorders arising out of cholestasis or portal hypertesion. The invention also provides, in part, polyhydroxylated bile acids for stimulating bile flow. New compounds 2[alpha],3[alpha],7[alpha],12[alpha]-tetrahydroxy-5[beta]-cholanoic acid and 3[alpha],4[alpha],7[alpha],12[alpha]-tetrahydroxy-5[beta]-cholanoic acid are disclosed, uses thereof and synthesis thereof.

Description

technical field [0001] The present invention provides polyhydroxylated bile acids and derivatives thereof for use in treating biliary disorders or stimulating bile flow. More specifically, the present invention provides polyhydroxylated bile acids and derivatives thereof for use in the treatment of biliary disorders resulting in or associated with cholestasis (cholestasis) or portal hypertension, or for stimulating bile flow. Background technique [0002] Bile is a complex secretion produced by the liver. It is stored in the gallbladder and is periodically released into the small intestine to aid in digestion. Bile components include cholesterol, phospholipids, bile pigments, and various toxins that are eliminated by the liver through biliary / fecal elimination. Bile salts are synthesized and actively secreted across the bile canalicular membrane, providing the osmotic force that drives bile flow. For bile formation, this is the rate-limiting step. Bile flow is necessary ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07J9/00A61K31/575A61P1/16
CPCA61K31/575C07J9/005A61P1/16A61P1/18A61P7/02A61P9/10A61P9/12A61P27/02A61P31/04A61P35/00
Inventor 林重庆王人学杨神予
Owner 山东青佰欣达医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com